Ectopic expression of PAX5 promotes maintenance of biphenotypic myeloid progenitors coexpressing myeloid and B-cell lineage-associated genes

Kristina Anderson,1 Corinne Rusterholz,1 Robert Månsson,1 Christina T. Jensen,1 Karl Bacos,1 Sasan Zandi,1 Yutaka Sasaki,1 Claus Nerlov,1,2 Mikael Sigvardsson,1,2 and Sten Eirik W. Jacobsen1

1Hematopoietic Stem Cell Laboratory, Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden, 2European Molecular Biology Laboratory, Monterotondo, Italy; 3Institution for Surgery and Biomedicine, Linköping University, Linköping, Sweden

The transcription factor PAX5 is a critical regulator of B-cell commitment and development. Although normally not expressed in myeloid progenitors, PAX5 has recently been shown to be frequently expressed in myeloid malignancies and to suppress expression of myeloid differentiation genes, compatible with an effect on the differentiation or maintenance of myeloid progenitors. However, previous studies in which PAX5 was ectopically expressed in normal myeloid progenitors in vivo and in vitro provided conflicting results as to the effect of PAX5 on myeloid development. Herein, we demonstrate that on ectopic expression of PAX5 in bone marrow multipotent stem/progenitor cells, cells with a biphenotypic B220+ GR-1/MAC-1+ phenotype are produced. These remain cytokine-dependent, but unlike control-transduced cells they sustain long-term generation of myeloid progenitors in vitro and remain capable of myeloid differentiation. Notably, PAX5+ B220+ GR-1/MAC-1+ myeloid progenitors coexpress, at the single-cell level, myeloid genes and otherwise B-cell–specific PAX5 target genes. These findings establish that ectopic expression of PAX5 introduces extensive self-renewal properties in otherwise short-lived myeloid progenitors. Along with the established ectopic expression of PAX5 in acute myeloid leukemia, this motivates a careful investigation of the potential involvement of ectopic PAX5 expression in myeloid and biphenotypic leukemias.

(HBB. 2007;109:3697-3705)

© 2007 by The American Society of Hematology

Introduction

The development of distinct mature blood cell lineages from hematopoietic stem cells (HSCs) is a highly ordered process involving a network of transcription factors and extracellular regulators.1 The paired domain transcription factor B-cell–specific activator protein (BSAP/PAX5), encoded by the Pax5 gene, is a critical regulator of B-cell commitment and development;3 and Pax5-deficient mice show a block in early B-cell development.5 Further, pro-B cells derived from Pax5-deficient mice reacquire an ability to differentiate into myeloid lineages both in vitro and in vivo.6,7 and more recent data have suggested that Pax5 might in part promote B-cell commitment in multipotent progenitors by repressing the expression of myeloid genes.7,9 These findings, combined with the fact that Pax5 normally is not expressed in the myeloid lineage in mice nor humans;2,10 would be compatible with ectopic expression of Pax5 in myeloid progenitors, resulting in suppression of myeloid programs and, as a consequence, suppression of myelopoiesis or expansion of early myeloid progenitors.

The reported expression of PAX5 message in numerous cases of acute myeloid leukemia (AML) and other myeloid malignancies,11-13 including the promyelocytic HL60 and megakaryoblastic MOLM-1 cell lines,14 could potentially be explained by ectopic expression of PAX5 contributing toward expansion of myeloid progenitors or precursors. However, previous studies in which PAX5 has been ectopically expressed in the myeloid lineage have not provided support for such an effect of PAX5 in myeloid progenitors. Rather, overexpression of PAX5 in vivo failed to demonstrate any significant effect on myelopoiesis.15,16 and in seemingly contrast to these data, in vitro studies focusing on the effect of PAX5 on terminal myeloid differentiation in response to all-trans-retinoic acid (ATRA) and myeloid growth factors suggested a suppressive effect of PAX5 on myeloid differentiation and survival.17,18

Herein, we pursued experiments aimed to reconcile these findings by focusing on the ability of ectopically expressed PAX5 to affect the maintenance as well as differentiation of myeloid progenitors in vitro. Notably, when cultured under myeloid conditions, PAX5-expressing cells coexpressed lymphoid PAX5 targets as well as myeloid genes and acquired a biphenotypic B220+ GR-1/MAC-1+ phenotype. These myeloid progenitors were sustained long-term in cultures supplemented with myeloid growth factors.

Materials and methods

Hematopoietic growth factors

Recombinant rat (rr) stem cell factor (SCF) and recombinant human (rh) granulocyte colony-stimulating factor (G-CSF) were generously provided by Amgen (Thousand Oaks, CA), rhFMS-like tyrosine kinase 3 ligand (FL), recombinant mouse (rm) interleukin-3 (IL-3), and rm granulocyte-macrophage colony stimulating factor (GM-CSF) by Immunex (Seattle, WA), rhIL-6 by Genetics Institute (Cambridge, MA); rhIL-7 by Sanofi (Labege Cedex, France); rh thrombopoietin (THPO) by Genentech (San Francisco, CA). Hepes, penicillin/streptomycin, ethanol, and propidium iodide were from Sigma-Aldrich (St. Louis, MO). Recombinant human interleukin-1 beta (IL-1 beta) was purchased from PeproTech (Rocky Hill, NJ). Recombinant human tumor necrosis factor alpha (TNF alpha) was a gift from Dr. R. Kastelein (Uppsala, Sweden). Recombinant human PAX5 (PAX5 trans activator protein) was expressed in Escherichia coli, purified, gel filtration chromatographed, and characterized by mass spectrometry. DNA transfection and transduction were carried out using lipofectamine (Invitrogen, New York, NY) and virus producing packaging cells (VSV-G), respectively.

BLOOD, 1 MAY 2007 • VOLUME 109, NUMBER 9
Francisco, CA); rh erythropoietin (EPO) by Boehringer Mannheim (Mannheim, Germany); and rh colony-stimulating factor 1 (CSF-1) by Cetus (Emeryville, CA). Unless otherwise indicated, predetermined optimal cytokine concentrations used in this study were as follows: 50 ng/mL rmSCF; 50 ng/mL rhGM-CSF; 25 ng/mL rmIL-6; 100 ng/mL rhIL-7; 100 ng/mL rhTHPO, 5 U/mL rhEPO, and 50 ng/mL rhCSF-1.

**Antibodies**

All antibodies were from PharMingen (Becton Dickinson, San Diego, CA). Antibodies used for cell surface staining were E13-161.7 (SCA-1), 2B8 (c-KIT), RA3-6B2 (B220), 6c3 (Ly5.1), TER119; A20 (CD45.1), 104 (CD45.2), 1D3 (CD45.1), 2B8 (c-KIT), RA3-6B2 (B220), 6c3 (Ly5.1), TER119; A20 (CD45.1), 104 (CD45.2), streptavidin-PE-Cy7 (Caltag, Burlingame, CA) were used to visualize biotin-conjugated primary antibodies.

**Isolation and FACS of stem and progenitor cell populations**

For fluorescence-activated cell sorting (FACS) 8- to 12-week-old congenic C57BL/6 mice (CD45.1 or CD45.2; Jackson Laboratories, Bar Harbor, ME) were used as bone marrow (BM) donors for purification of lineage (LIN) low and negative, SCA-1– and c-KIT–expressing (LSK) HSCs, performed as previously described.19 LIN-c-KIT(SCA-1)IL-7Rα-FcyR(CD34)+ common myeloid progenitors (CMPs), LIN-c-KIT(SCA-1)IL-7Rα-FcyR(CD34)+ megakaryocyte/erythrocyte lineage-restricted progenitors (MEPs), and LIN-c-KIT(SCA-1)IL-7Rα-FcyR(CD34)+ granulocyte/macrophage lineage-restricted progenitors (GMPs) were purified by incubating adult BM cells with a cocktail of lineage-specific antibodies including anti-IL-7Rα antibody. Lineage-depleted cells were subsequently stained with FITC-conjugated anti-CD34, PE-conjugated anti-CD16/32 (FCγRIII), APC-conjugated anti-c-KIT, and biotinylated anti-SCA-1 antibodies. The biotinylated antibody was visualized with streptavidin-PE-Cy7. AA4.1 C1D3 CD19+ CD4– CD38+ CD19+ pro-B cells and double-positive (DP) CD4+ CD8+ thymic progenitors were sorted from normal adult BM and thymuses, respectively. Cells with low viability were excluded from the sorting gate by staining with 7-aminoactinomycin D (7AAD; Sigma-Aldrich, St. Louis, MO). Stained cells were sorted on a FACSVantage or FACS Diva Cell Sorter (Becton Dickinson).

**Retroviral constructs**

The human PAX5 cDNA, generously provided by Dr Meinrad Busslinger (Vienna Biocenter, Vienna, Austria), was inserted into a MSCV promoter driven retroviral vector 5′ of an internal ribosome entry site (IRES) followed by enhanced green fluorescence protein (eGFP). The construct was stably integrated in the GP+E86 cell line (a generous gift from Arthur Bank, College of Physicians and Surgeons, Columbia University, New York, NY) and the selected clone produced a virus titer of around 1.14 × 10⁸ transducing units (TU)/mL. The control vector containing yellow fluorescent protein (YFP, from Dr James Hagman, University of Colorado Health Sciences Center, Denver, CO) was introduced into the virus producer 293 GPG cell line to generate media with a virus titer of 1.1 × 10⁷ TU/mL. Another control vector (generous gift from Drs Thomas Relander and Johan Richter, Department of Gene Therapy, Lund, Sweden) contained eGFP upstream of an IRES and a neomycin phosphotransferase (NEO) with virus titer 3.6 × 10⁶ TU/mL.

**Transduction and ex vivo culture of transduced progenitors**

Hematopoietic cell cultures were performed either in serum-free X-vivo 15 medium (BioWhittaker, Walkersville, MD) supplemented with 1% bovine serum albumin (BSA; StemCell Technologies, Vancouver, BC, Canada), 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, 100 U/mL penicillin, 100 U/mL streptomycin (hereafter serum-free medium [SFM]) or in Iscove modified Dulbecco medium (IMDM), supplemented with 20% fetal calf serum (FCS), both from BioWhittaker (Verviers, Belgium), 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, 100 U/mL penicillin, 100 U/mL streptomycin (hereafter serum-containing medium [SCM]). LSK cells were prestimulated in SFM supplemented with SCF, IL-3, IL-6, FL, and either IL-7 or THPO for 48 hours and subsequently transduced on retrovencin-coated (Takara Bio, Otsu, Japan) and virus-preloaded non–tissue culture-treated 96-well plates in SFM with the same cytokine combination as indicated for another 48 hours. Subsequently, cells were washed and transferred either into SFM supplemented with SCF, FL, and IL-7 for pro-B cell assay or into SCM supplemented with SCF, GM-CSF, G-CSF, and IL-3 for myeloid progenitor assay. Cells were analyzed for YFP/GFP expression another 72 hours later using FACS Calibur. Transduction efficiency was defined as the percentage of YFP/GFP positive cells 7 days after transduction. For evaluation of cytokine dependence and potential phenotype change, GFP+ B220+GR-1+MAC-1+ cells from 24 days of culture in SCM under myeloid conditions were washed and transferred either to SCM or SFM supplemented with only medium or one of the following cytokines: GM-CSF, IL-3, G-CSF, FL, IL-7, EPO, THPO, and CSF-1. Cytokines were resupplied twice a week and cells were split 2 or more times per week to keep cell density below 1 × 10⁶ cells/mL.

**Myeloid progenitor assay**

For detecting committed myeloid progenitors, a granulocyte-macrophage colony-forming unit (CFU-GM) assay was performed. GFP+ control and PAX5-transduced cells obtained by FACS were plated in methylcellulose (M3434; StemCell Technologies) supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 U/mL streptomycin, 0.1 mM 2-mercaptoethanol, 10 ng/mL rmSCF, 25 mg/mL rhFL, 10 ng/mL rmIL-3, 25 ng/mL rhG-CSF, 25 ng/mL rmGM-CSF, and 100 ng/mL rhTHPO in 35-mm Petri dishes. Colonies (>50 cells) in methylcellulose were scored using an Olympus IX70 inverted microscope (Olympus, Hamburg, Germany) equipped with LCPPlan FI 40×/0.60 Ph2 and UPlan FI 10×/0.30 Ph1 objectives (Olympus, Tokyo, Japan) after 14 days of incubation at 37°C and 5% CO2. Photographs of colonies in methylcellulose were captured with a Sony DCK-5000 3CCD camera (Sony, Tokyo, Japan), using Infan View software. Images were further processed with Adobe Photoshop software (Adobe Systems, Mountain View, CA).

**Cell morphology**

Cells (10⁴) from liquid cultures or individual colonies were centrifuged onto glass slides using a Cytospin 3 (Shandon, Labex Instrument, Helsingborg, Sweden), stained for 5 minutes in May–Grünewald stain and 20 minutes in Giemsa stain (both from Histolab, Gothenburg, Sweden), thereafter washed, dried, and finally analyzed for lineage-specific cell type by microscopy (Olympus BX51TF, Olympus, Hamburg, Germany). Photographs of cytospins and colonies in methylcellulose were captured with either Olympus DP70 (Olympus) or Sony DCK-5000 3CCD camera, using an Olympus BX51TF microscope (Olympus, Tokyo, Japan) equipped with a UPlan FL 100×/1.30 oil-immersion objective lens. Photographs of cytospins were captured with an Olympus DP70 camera using DP controller software. Images were further processed with Adobe Photoshop software.

**Southern blot analysis**

gDNA was extracted by lysis of cells in 250 mM Tris, pH 8.0, 150 mM NaCl, 10 mM EDTA, and 0.1% SDS. The mixture was incubated overnight at 56°C with Proteinase K (Invitrogen, Stockholm, Sweden) and DNA purified by phenol extraction and precipitated by addition of 0.7 volumes of isopropanol (Sigma, Stockholm, Sweden). The precipitated DNA was washed 2 times with 70% ethanol, dried, and redissolved in water. Approximately 10 μg DNA was digested with HindIII (Boehringer Mannheim) and size-fractionated on 0.8% agarose gel. After transfer to a nylon membrane by capillary blotting, the membrane was hybridized with 32P-labeled random primed probe in 6 × SSC, 5 × Denhart solution, 0.1% agarose gel. After transfer to a nylon membrane by capillary blotting, the membrane was hybridized with 32P-labeled random primed probe in 6 × SSC, 5 × Denhart solution, 0.1% agarose gel. After transfer to a nylon membrane by capillary blotting, the membrane was hybridized with 32P-labeled random primed probe in 6 × SSC, 5 × Denhart solution, 0.1% agarose gel.
0.1 × SSC with 0.1% SDS for 5 to 10 minutes. The hybridized membrane was subjected to autoradiography.

**Linker-mediated polymerase chain reaction**

For linker-mediated polymerase chain reaction (LM-PCR), single myeloid colonies (CFU-GMs) were picked from methylcellulose and gDNA was extracted using Qiam DNA mini kit (Qiagen, Sollna, Sweden) according to the manufacturer’s instructions. gDNA was digested with TaqI in 20 μL reaction and denatured at 95°C for 10 minutes in the presence of 1 μM solution of primer 1. After cooling on ice, 1 μL of 5 mM solution of dNTP (Roche, Bromma, Sweden) and 5 U Klenow (Roche) enzyme were added to allow the formation of double-stranded blunt end templates. The dNTP (Roche, Bromma, Sweden) and 5 U Klenow (Roche) enzyme were added to allow the formation of double-stranded blunt end templates. The DNA was then diluted to 50 μL by the addition of distilled water and subsequently precipitated with 5 μL of 3 M NaAc, pH 5.2, and 125 μL 95% ethanol. After freezing, the pellets were collected by centrifugation and washed twice with 70% ethanol. The dry pellets were redissolved in 15 μL water, 2 μL ligation buffer, and 2 μL annealed linker oligonucleotide (10 μM). Subsequently, 5 U T4 DNA ligase (Roche) was added to the reaction and incubated at 20°C overnight. Then, 2 μL of template was used for PCR 1 together with primer 2 and linker sense primer for 30 cycles of amplification (94°C, 45 seconds; 56°C, 45 seconds; 72°C, 60 seconds). PCR product 1 (2 μL) was diluted in 100 μL water and 2 μL diluted template was used for PCR 2 together with primer 3 and linker sense primer for another 30 cycles of amplification (94°C, 45 seconds; 61°C, 45 seconds; 72°C, 60 seconds). The PCR products were transferred to a nylon membrane and the filters were hybridized to T4 PNK-labeled oligonucleotide directed against theLTR (LMHyb). Primer 1: 5'-TTACACAGATATCTGTGTTGG-3'; primer 2: 5'-CTGGTCTCTCTTGCTCTTACAC-3'; primer 3: 5'-GACTGGAATCTCCTATGCACTG-3'; linker primer sense: 5'-GGGTTACCCGGAGATCTGAATTC-3'; linker primer antisense: 5'-GAATTACGATC-3'; LMHyb: 5'-TGTCAAGGCGATGAAATACATACACGTG-3'.

**Protein extracts and EMSA**

Nuclear extracts were prepared according to Schreiber et al22 and electrophoretic mobility shift assay (EMSA) performed as previously described.23 Nuclear extracts (5 μg) were incubated with 32P-labeled double-stranded probes (20 000 cpm, 3 fmol) and either anti-PAX5 (sc-1974), anti-CCAAT enhancer binding protein-α (C/EBPa; sc-61 X; both from Santa Cruz Biotechnology, Santa Cruz, CA), or competitor DNA. The samples were separated on 6% polyacrylamide TBE gel, which was dried and subjected to autoradiography.23 CD19-Pax5 sense: 5'-GCGAGACACCATGGTGATGTCGCTTGAG-3'; CD19-Pax5 antisense: 5'-CTGGAGGCGCTTCAACCATGGTGCTG-3' oligonucleotides were used.

Cell lines and global gene expression (Affymetrix) analysis are presented in the supplemental methods (available on the Blood website; see the Supplemental Materials link at the top of the online article).

**RT-PCR and Q-PCR**

Total RNA was prepared using TRizol (Gibco, Paisley, Scotland). Obtained RNA samples were reverse transcribed using SuperScript II and random hexamers (Invitrogen) according to protocol supplied by the manufacturer and as previously described.22 Quantitative reverse transcription-PCR (Q-RT-PCRs) were performed by mixing 2 × TagMan universal PCR master mix, 20 × Assays-on-Demand (primer-MGB-probe), RNase-free H2O, and 5 μL cDNA to a final reaction volume of 20 μL.

The following TaqMan Assays-on-Demand probes were used for mb-1 (Cd79a): Mm00432423_m1; Blik: Mm00456139_m1; Rag2: Mm05013000_m1; Cd19: Mm00515420_m1; Ebf1: Mm01288947_g1; Il7ra: Mm00434295_m1; Csf2ra: Mm00433831_g1; Cebpa: Mm00512883_s1; Cebpa: Mm02030636_s1; Gata1: Mm0048678_g1. Sequences for Assay-by-Design Q-PCR (Applied Biosystems, San Diego, CA) were as follows: Rag1: forward 5'-TGTGGGAGCAAGTGCTCTGCTG-3'; reverse 5'-TCTATCACTTCGTGTCATACG-3'; MGB-probe 5'-ATGGCTGCCCTCTCTTG-3'; A5: forward 5'-GGAACACCCAGGCCTACGCATGCATGTC-3'; reverse 5'-CTCCCCGTTGGAGATGACG-3'; MGB-probe 5'-CCGGCAAGCTCTCGGT-3'; Nr2: forward 5'-GACUTGGGCAAGATCATGTCATACG-3'; reverse 5'-GGCTCAAAGATGCTCTCGTGAACG-3'; MGB-probe 5'-CTGACGCTGCGAG-3'. Normalizing was carried out against Hprt expression levels. For conventional PCR one-twentieth of the RT reaction was amplified using 1 U Taq polymerase (Life Technologies, Bethesda, MD) in the manufacturer’s buffer supplemented with 0.2 mM dNTP in a total volume of 25 μL. Oligonucleotides: Pax5: forward 5'-CTACAGGCTCTCGTACGCG-3'; reverse 5'-GTCTCGGGCTCGTGAAATAGG-3'; 5684: forward 5'-GAGGAATACATGAGAGATGCTCGTACGTTG-3'; reverse 5'-AAGCAGGCTGTTGTCGG-3'.

**Immunoglobulin recombination PCR analysis**

gDNA was prepared using TRizol (Gibco) according to the manufacturer's instructions. IgH D-J rearrangements and germline DNA were amplified in the same reaction by 33 cycles (94°C, 30 seconds, 60°C, 45 seconds, and 72°C, 1 minute) using the DH and J3 primer at 1 μM and the Mu0 (amplifies germline DNA together with J3) primer at 0.1 μM final concentration. The PCR products were blotted and hybridized as described above under “Southern blot analysis.” A J3-specific 32P-labeled oligonucleotide (HJ3) was hybridized to the filters at 45°C overnight; thereafter the filters were washed and subjected to autoradiography as above. Oligonucleotides: DH: 5'-GAAATTCG(A/C)TTTTTGT(C/G)-CCAGGATCTACTCGT-3'; J3: 5'-GTCTGATATCTCACAAGAGTCGCTGACGACCTGTTG-3'; Mu0: 5'-CAGCGATCAGAACTGCGCCTTGATGAAATACC-3'; HJ3: 5'-AGACATGAGCGAGATTCCTG-3'.

**Analysis of single cells by RT-PCR**

Multiplex single-cell RT-PCR analysis of GFP(PAX5)*B220*GR-1/MAC-1* cells was performed according to the methods described previously.19,24 Single cells were deposited by a single-cell depositor coupled to a FACSDiva into 96-well PCR plates containing 4 μL lysis buffer followed by multiplex PCR.24 Aliquots of second-round PCR products were subjected to gel electrophoresis and visualized by ethidium bromide staining on E-gels (Invitrogen). Oligonucleotides: sub-1: external forward 5'-CTCTCCTCTCTGTCATACG-3'; reverse 5'-GAAAAGATGGCGAAGACCC-3'; internal forward 5'-GTATGAGGGGCTTTGG-3'; Cebpa: external forward 5'-ACTTTCTGACCTCTTGTCG-3'; reverse 5'-GGTTTCGACCATGACTCC-3'; internal forward 5'-CTGTTCTCTACCTACCGTG-3'; reverse 5'-CAAGGGGTGTAAGCTGTTG-3'; Hprt: external forward 5'-GGGGGCCTATAAGTTTCTTGC-3'; reverse 5'-TCCAAACCTTGGAGGCTCC-3'; internal forward 5'-GGTTTCTCTGAGGCTGTTG-3'; reverse 5'-TGGGCTGACTGCTTAACC-3'.

**Statistics**

Student t test was performed for statistical analyses to assess differences between the groups.

**Results**

**Enforced expression of PAX5 promotes development and proliferation of B-cell progenitors and immortalization of biphenotypic myeloid progenitors**

Retroviral overexpression of human PAX5 was targeted to multipotent LSK cells that were subsequently cultured under conditions compatible with B-lymphocyte and myeloid development (see “Materials and methods”). We have previously shown that purified multipotent LSK cells cultured in FL and IL-7 efficiently develop into pro-B cells under serum-free conditions.25 Later we observed that when transfected under conditions containing myeloid cytokines, the ability of LSK cells to generate pro-B cells is severely impaired (K.A. and S.E.W.J., unpublished observation, October 2001). By 14 days of culture in the presence of SCF, FL, and IL-7, control and PAX5-transduced cells had expanded at comparable
We next investigated how enforced PAX5 expression might affect myeloid differentiation from multipotent LSK cells. Whereas previous in vivo studies have suggested that myeloid development from HSCs is not affected by PAX5,15,16 other in vitro studies have implied that PAX5 under certain growth factor conditions can suppress myeloid development.17,18

In an attempt to reconcile these findings we cultured control vector and PAX5-transduced LSK cells under conditions promoting myeloid commitment and differentiation. Strikingly, under these conditions, PAX5-overexpressing cells showed enhanced and sustained expansion when compared to control vector-transduced cells (Figure 2A). The finding that control cultures drop off after 25 to 50 days reflects that the normal progenitors, as expected, eventually are exhausted in such cultures (Figure 2A). Although the initial transduction efficiency was comparable, the percentage of GFP+ cells gradually increased in PAX5 but not control-transduced cultures (Figure 2B). Notably, whereas GFP+ control-transduced cells, as expected, were predominantly B220–GR-1/MAC-1+ myeloid cells, PAX5-transduced cultures were dominated by a rapidly expanding biphenotypic GFP(PAX5)+B220+GR-1/MAC-1+ population, which was already detectable at day 5 and by day 24 represented most of the cells (Figure 2C-D). No other B-cell surface antigens, such as IL-7Rα, BP-1, CD19, or IgM, were expressed on biphenotypic GFP(PAX5)+B220+GR-1/MAC-1+ cells nor were erythroid (TER119) or T-cell (CD3) antigens (K.A. and S.E.W.J., unpublished observations, May 2002).

Because B220, GR-1 and MAC-1 antigens are expressed not only on myeloid cells, but also on dendritic cells (DCs),26 including plasmacytoid DCs (PDCs), we performed phenotypic analysis of PAX5-transduced cells to investigate expression of several cell surface antigens expressed on DCs. PAX5-expressing B220+GR-1/MAC-1+ cells did not express CD4 and CD8, but expressed CD11c and a marker (CD86) previously shown to be expressed on myeloid cells, but also on DCs,26 including PDCs. We also performed phenotypic analysis of control-transduced cells under similar conditions and found that control-transduced cells expressed high levels of MAC-1 (in contrast to PDCs, which have been shown to be expressed on PDCs, whereas CD11c was expressed on 0.2% and CD86 on 0.8% of GFP(PAX5)+B220+GR-1/MAC-1+ cells, respectively (Figure S1). Moreover, PAX5-transduced cultures expressed high levels of MAC-1 (in contrast to PDCs, which express MAC-1 at low levels), displayed a typical myeloid morphology (Figure 3), lacked expression of I7r, and were not DJ rearranged, in contrast to what has been reported for PDCs.26
Importantly, whereas control-transduced cells ceased to proliferate in long-term culture, cells with a GFP(PAX5)+B220+GR-1/MAC-1+ phenotype could be sustained and expanded for up to 275 days (longest time investigated; Figure 2D). The fact that GFP(PAX5)+B220+GR-1/MAC-1+ cells (and not GFP−cells) expanded enormously in long-term culture indicates that PAX5-transduced cells had a competitive advantage and that this effect is cell intrinsic. Morphologically, the biphenotypic GFP(PAX5)+B220+GR-1/MAC-1+ cell population was highly heterogeneous, consisting of immature as well as mature myeloid cells, predominantly of the granulocytic but also the monocytic lineages, whereas control cultures, as expected, already at day 25 predominantly contained mast cells and macrophages with a few immature and mature granulocytes (Table 1; Figure 3). In contrast to control cultures, PAX5-transduced cultures also contained a low but consistent number of blast cells, compatible with sustaining a population of myeloid progenitors. Importantly, similar proportions of immature and mature granulocytes were observed at later time points when control cultures were no longer able to sustain any myeloid cell production (K.A. and S.E.W.J., unpublished observation, June 2002).

Table 1. Ectopic PAX5 expression sustains long-term generation of granulocytes

<table>
<thead>
<tr>
<th></th>
<th>Blasts</th>
<th>Immature</th>
<th>Mature</th>
<th>Monocytes/macrophages</th>
<th>Mast cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0 (0; 0)</td>
<td>0.6 (0.2; 1.2)</td>
<td>30.7 (0.61; 30.5)</td>
<td>35.7 (9.65; 28)</td>
<td>33 (2.91; 50.3)</td>
</tr>
<tr>
<td>PAX5</td>
<td>2.7* (2-3; 0.6)</td>
<td>41* (37.46; 4.6)</td>
<td>43.6 (40-50; 5.5)</td>
<td>8.1 (4.11; 3.8)</td>
<td>4.6 (2.6; 2.3)</td>
</tr>
</tbody>
</table>

Control or PAX5-transduced LSK cells were cultured with SCF, GM-CSF, IL-3, and G-CSF for 24 days at which time cytoplasm slides were stained with May-Grünwald-Giemsa (MGG) and evaluated under a light microscope. Data represent mean percentages (range; SD) of blasts, granulocytes (immature and mature), monocytes/macrophages, and mast cells derived from control and PAX5-transduced lines in 3 different experiments. *P < .05.
erythroid-burst-forming units (BFU-Es) nor megakaryocyte colonies were detected in both control and PAX5-transduced cultures (K.A. and S.E.W.J., unpublished observations, September 2006). Thus, this finding demonstrates that overexpression of PAX5 leads to enhanced maintenance of GM progenitors in long-term culture.

We next investigated whether the sustained growth of GFP(PAX5)β220-GR-1/MAC-1+ biphenotypic cells is cytokine dependent. Whereas GFP(PAX5)β220-GR-1/MAC-1+ cells expanded well in the myeloid cytokines, such as GM-CSF, and were also sustained in IL-3, they rapidly lost viability in the absence of cytokines (Figure 4C-D), and neither EPO, THPO, FL, nor IL-7 had any ability to promote viability, proliferation, or differentiation along the erythroid, megakaryocytic, and lymphoid lineages, respectively (K.A. and S.E.W.J., unpublished observations, May 2002).

To investigate whether the sustained GM progenitors in PAX5-transduced cultures are monoclonally or oligoclonally derived, we performed Southern blot analysis of HindIII-digested gDNA using a probe directed against PAX5. We observed multiple different integration sites of the retroviral vector, suggesting that the generated GFP(PAX5)β220-GR-1/MAC-1+ cells were sustained through oligoconal or polyclonal expansion and that the biphenotype and expansion of GFP(PAX5)β220-GR-1/MAC-1+ cells was related to the expression of PAX5 rather than to any specific vector integration sites (Figure 5A). To verify the oligoclonal nature of PAX5-transduced cells and exclude that single clones contained the multiple integration sites observed, LM-PCR was performed on 9 individual colonies derived from a single cell line. Several different viral integration patterns could be seen in individual colonies (Figure 5B). Thus, although we cannot exclude the presence of a dominant integration site with the degree of resolution obtained with Southern blot of PCR products, these data support that the GM progenitors sustained by GFP(PAX5)β220-GR-1/MAC-1+ cells are oligoclonally derived.

To verify that the expressed PAX5 protein was able to bind DNA, we performed EMSA with nuclear extracts from 3 independently generated GFP(PAX5)β220-GR-1/MAC-1+ lines (1, 2, and 3) and the PAX5-binding site from the mouse CD19 promoter. One prominent complex was detected using nuclear extracts from the pre-B cell line 40Ei and all 3 analyzed GFP(PAX5)β220-GR-1/MAC-1+ lines (Figure 5C). This complex was disrupted by the addition of anti-PAX5 antibody but not control (anti-C/EBPα) antibody demonstrating that the cells express high levels of functional PAX5 protein.

To resolve if any of the PAX5 protein detected by the EMSA was due to activation of the endogenous Pax5 gene we performed RT-PCR analysis using mouse-specific primers (Figure 5D). Mouse Pax5 transcript was detected in the pre-B cell lines 40Ei and 70Z/3, whereas no message was detected either in the myelomonocytic cell line WEHI3 or in any of the 3 GFP(PAX5)β220-GR-1/MAC-1+ cell populations. This suggests that enforced expression of human PAX5 protein in myeloid progenitor cells otherwise negative for endogenous Pax5 results in development of immortalized β220-GR-1/MAC-1+ biphenotypic cells.

**PAX5 expressing biphenotypic β220-GR-1/MAC-1+ cells coexpress otherwise myeloid- and lymphoid-associated genes**

To investigate whether GFP(PAX5)β220-GR-1/MAC-1+ cells also are biphenotypic with regard to expression of myeloid- and lymphoid-lineage programs, we performed microarray analysis using cells from one of the experiments (Exp no. 1) and compared the RNA expression patterns in these cells to that in Abelson-transformed pre-B cell lines (18-81 and 230-238) and the myelomonocytic cell line WEHI3 (Figure S2; Table S1). This comparison revealed that the GFP(PAX5)β220-GR-1/MAC-1+ cells had a unique gene expression pattern with significant activity of genes found selectively either in the pre-B cell lines or the myeloid cell line. Using present (P)/absent (A) classification on the pre-B/myeloid cell-associated genes, we identified among the pre-B cell-associated genes, mb-1 and Blnk, which encode functional components of the B-cell receptor, being expressed in the GFP(PAX5)β220-GR-1/MAC-1+ cells.

To verify that the long-term cultured GFP(PAX5)β220-GR-1/MAC-1+ cells expressed a mix of lymphoid and myeloid genes, we performed Q-RT-PCR analysis of a set of lineage-associated genes. This revealed that the GFP(PAX5)β220-GR-1/MAC-1+ cells expressed significant levels of the B-lymphoid-associated PAX5 targets mb-1, Blnk, and Rag2, whereas Cd19 expression was low or undetectable (Figure 6A). We could only detect very low or no expression of Ebf1, h-3, Rag1, and II7r in GFP(PAX5)β220-GR-1/MAC-1+ cells (Figure 6A). As expected based on their morphology and sustained CFU-GM activity,
biphenotypic cells did, however, express the myeloid-associated genes \textit{Csf2ra}, \textit{Cebpa}, \textit{Nfe2}, and \textit{Gata1} (Figure 6A). Although the comparison between the PAX5-transduced cells and the myelomonocytic and pre-B cell lines investigated was useful to establish whether myeloid and B-cell genes were coexpressed in GFP(PAX5)/H11001 B220/H11001 GR-1/MAC-1/H11001 cells, they were less relevant for establishing whether overexpression of PAX5 would result in altered levels of these genes. Thus, we next compared the expression of \textit{mb-1}, \textit{Blnk}, and several key myeloid genes in GFP/H11001 cells purified from control as well as PAX5-transduced cultures at 2 time points (day 4-5 and 12-14; Figure 6B). Importantly, these 2 early time points were chosen to ensure that the control and PAX5-transduced cells were as comparable as possible. These experiments confirmed the specific up-regulation of \textit{mb-1} and \textit{Blnk} by PAX5 and also demonstrated that the investigated myeloid genes \textit{Cebpa}, \textit{Cebpe}, \textit{Csf2ra}, and \textit{Gata1} were expressed at similar levels in control and PAX5-transduced cultures (Figure 6B).

Next we analyzed immunoglobulin heavy (IgH) chain D to J (DJ) recombination in the GFP(PAX5)/H11001 B220/H11001 GR-1/MAC-1/H11001 cells by PCR. The analysis used a set of 3 primers designed to amplify either the germline (GL) gene or any recombination event between D regions and J1-J3. Polyclonal rearrangements were easily detectable in the BM DNA, whereas no rearrangements could be detected in the GFP(PAX5)/H11001 B220/H11001 GR-1/MAC-1/H11001 cell populations (Figure 7A). These data indicate that GFP(PAX5)/H11001 B220/H11001 GR-1/MAC-1/H11001 cells do not contain committed B-cell progenitors, but rather myeloid cells with a unique mixed gene expression pattern imposed on them by ectopic expression of PAX5.

Even though the detection of both myeloid and B-lymphoid genes as well as coexpression of B220 and GR-1/MAC-1 on the cell surface supports the idea that PAX5 immortalized a myeloid precursor population coexpressing predominantly myeloid but also some lymphoid genes, Q-PCR could not exclude that the lymphoid and myeloid genes might be expressed in different subsets of

**Figure 6.** GFP(PAX5)/H11545 B220/H11545 GR-1/MAC-1/H11545 cells coexpress genes characteristic for both lymphoid and myeloid cells. (A) Diagrams of TaqMan Q-RT-PCR analysis of gene expression in 2 pre-B cell lines 230-238 (B1) and 18-81 (B2), WEHI3 cell line (W), and 3 GFP(PAX5)/H11001 B220/H11001 GR-1/MAC-1/H11001 long-term cell lines (Exp no. 1, 190 days; Exp no. 2, 80 days; Exp no. 3, 65 days) independently generated through PAX5 transduction of LSK cells. (B) GFP+ cells were sorted from control (●) and PAX5-transduced (■) cultures at indicated times and RNA extracted for gene expression analysis. Differences in cDNA input were compensated by normalizing against \textit{Hprt} expression levels. Mean (SD) values of 3 experiments. *P < .05. All water controls were negative (data not shown).

**Figure 7.** GFP(PAX5)/H11545 B220/H11545 GR-1/MAC-1/H11545 cells coexpress lymphoid and myeloid programs at the single-cell level. (A) Polyclonal IgH chain D to J (DJ) recombination was detected in BM cells but not in the GFP(PAX5)/H11001 B220/H11001 GR-1/MAC-1/H11001 cell populations from experiments 1, 2, 3, 5, and 6 analyzed by PCR. The analysis used a set of 3 primers designed to amplify either the germline (GL) gene or any recombination event between D regions and J1-J3. (B) Expression of \textit{mb-1}, \textit{Cebpe}, and \textit{Hprt} in cells from populations (sorted by FACS) of common myeloid progenitors (CMPs), granulocyte-macrophage progenitors (GMPs), megakaryocyte-erythrocyte progenitors (MEPs), as well as, pro-B and DP T-cell progenitors (pro-T). (C) Co-expression of \textit{mb-1} and \textit{Cebpe} in single GFP(PAX5)/H11001 B220/H11001 GR-1/MAC-1/H11001 cells, as evaluated by multiplex single-cell RT-PCR.19 Asterisk indicates water control.
progenitors. Thus, to get conclusive evidence for coexpression of myeloid and lymphoid genes in the immortalized myeloid progenitors, we further performed single-cell multiplex PCR on GFP(PAX5)+ B220+GR-1+/MAC-1+ cells.19 Purified myeloid- and lymphoid-restricted progenitors including CMP, GMP, MEP, pro-B cells, and DP T-cell progenitors were used to confirm lineage specificity of the gene expression patterns (Figure 7B). Notably, every GFP(PAX5)+ B220+GR-1+/MAC-1+ cell that expressed the housekeeping gene Hprt coexpressed the B-lineage–specific PAX5 target gene mb-1 and the myeloid associated gene Cebpe (Figure 7C).10

Discussion

The present studies demonstrate that PAX5 in addition to favoring B-cell commitment and development from multipotent stem/progenitor cells, if ectopically expressed in the myeloid lineage pathway, promotes enhanced maintenance of otherwise short-lived myeloid progenitors with a biphenotypic B220+GR-1+/MAC-1+ cell surface phenotype. Notably, biphenotypic GFP(PAX5)+ B220+GR-1+/MAC-1+ cells coexpress lymphoid PAX5 target genes mb-1, Blnk, and Rag2, along with myeloid genetic program. Importantly, multiplex single-cell PCR demonstrated that this coexpression did indeed reflect coexpression of B-cell–specific PAX5 target genes and myeloid genes in the same single cells rather than in different subpopulations. In fact, virtually every GFP(PAX5)+ B220+GR-1+/MAC-1+ cell coexpressed myeloid and PAX5 target genes.

Although GFP(PAX5)+ B220+GR-1+/MAC-1+ cultures sustained a population of myeloid progenitors in long-term culture, these were, as control-transduced progenitors, able to differentiate into fully mature granulocytes, macrophages, and mast cells, in agreement with previous studies demonstrating that ectopic PAX5 expression is fully compatible with normal myeloid differentiation in vivo.15,16 In fact, also using our vectors, PAX5-transduced LSK cells contributed normally to myelopoiesis in vivo (K.A. and S.E.W.J., unpublished observation, March 2002). Thus, myeloid progenitors expressing PAX5 appear to have extensively enhanced self-renewal potential but remain capable of balanced normal myeloid differentiation. Moreover, PAX5-transduced myeloid progenitors have an oligoclonal origin, as picked clones derived from individual progenitors in a CFU-GM assay showed largely distinct (although also overlapping) integration sites. Thus, these findings indicate that PAX5 promotes sustained polyclonal regeneration of myeloid progenitors, which remain dependent on GM-CSF or IL-3 stimulation. In agreement with this, all GFP(PAX5)+ B220+GR-1+/MAC-1+ cells expressed high levels of Csf2ra and Il3.

Our findings are in striking contrast to those of Chiang and Monroe who reported that overexpression of PAX5 in myeloid progenitors was accompanied by reduced terminal differentiation and enhanced apoptosis, and reduced GM-CSFRe expression.17,18 Although the reason for this discrepancy remains unclear, it could reflect the different myeloid differentiation conditions used in the 2 studies. In fact, during the first 8 days of cultures when Chiang and Monroe used similar conditions as ours, neither study showed any suppressive effects of PAX5 on myelopoiesis. It was first after 8 days when they switched to culture conditions (including ATRA) forcefully promoting terminal myeloid differentiation that they observed reduced cellular output.17 In contrast, under our conditions, which also included early stem/progenitor factors such as SCF, we observed that ectopic PAX5 expression prohibited the exhaustion of myeloid progenitors normally seen in such cultures. Regardless, our studies establish that ectopic expression of PAX5 introduces extensive self-renewal properties in otherwise short-lived myeloid progenitors. The potential mechanism for this profound effect on myeloid progenitor maintenance remains to be established but is unlikely to exclusively be explained by the reported ability of PAX5 to down-regulate expression of myeloid genes.7-9

Our findings are of particular interest in light of the observation that PAX5, normally being B-cell restricted,7-4,27 is frequently ectopically expressed in myeloid malignancies.11,12 The fact that PAX5 is widely expressed in the myeloid blasts in these cases,11,12 and also in clonally derived myeloid leukemic cell lines,29 virtually excludes that this finding is due to contaminating PAX5+ B cells. Interestingly, considering the B220+GR-1+/MAC-1+ biphenotype of the sustained myeloid progenitors expressing PAX5, ectopic PAX5 expression has also been observed in human biphenotypic leukemias.12

It is unlikely that ectopic PAX5 expression in itself can induce myeloid leukemia since GFP(PAX5)+ B220+GR-1+/MAC-1+ cells generated in vitro failed to reconstitute normal or leukemic myelopoiesis on transplantation (K.A. and S.E.W.J., unpublished observations, July 2002). Thus, combined with the frequent ectopic expression of PAX5 in myeloid leukemia, our data would rather suggest that ectopic PAX5 expression in some cases might be involved in the progression of AML.

Acknowledgments

This work was supported by grants from the Swedish Cancer Society, the Swedish Research Council, and the Swedish Foundation for Strategic Research. The Lund Stem Cell Center is supported by a Center of Excellence grant from the Swedish Foundation for Strategic Research.

The authors are grateful to Dr Meinrad Busslinger for generously providing PAX5 cDNA, Drs Thomas Relander and Johan Richter for MGIN vector, Dr James Hagman for MIY vector, and Arthur Bank for the GP+E86 cell line. We also thank Ewa Sitnicka, Natalija Buzza-Vidas, Jörg Cammenga, Carole Ramirez, Kim Theilgaard-Moench, and Jennifer Antonchuk for valuable technical assistance and advice.

Authorship

Contribution: K.A. designed and performed research, contributed vital new reagents and analytical tools, analyzed data, and wrote the paper; C.R. designed and performed research, contributed vital new reagents, and analyzed data; R.M. designed and performed research, contributed vital new analytical tools, analyzed data, and wrote the paper; C.T.J. performed research; K.B. performed research; S.Z. performed statistical validation of data; Y.S. designed research; C.N. designed research and analyzed data; M.S. designed and performed research, contributed vital new analytical tools, analyzed data, and wrote the paper; and S.E.J. designed research, analyzed data, and wrote the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.
Correspondence: Sten Eirik W. Jacobsen, Hematopoietic Stem Cell Laboratory, Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, BMC B10, Klinikgatan 26, 221 84 Lund, Sweden; e-mail: sten.jacobsen@med.lu.se.

References


Ectopic expression of PAX5 promotes maintenance of biphenotypic myeloid progenitors coexpressing myeloid and B-cell lineage-associated genes

Kristina Anderson, Corinne Rusterholz, Robert Månsson, Christina T. Jensen, Karl Bacos, Sasan Zandi, Yutaka Sasaki, Claus Nerlov, Mikael Sigvardsson and Sten Eirik W. Jacobsen